Roche Pharmaceutical Development and Sales Overview

Immunology franchise Actemra COVID-19 sales declining and Esbriet generic competition CHFM 2,500 +13% +5% +1% 2,000 1,500 1,000 500 0 Q3 19 Q3 20 Q321 ■Rituxan/MabThera (RA) Actemra SC CellCept Esbriet YoY CER growth Actemra IV Xolair Pulmozyme Other -25% Q3 22 Immunology Q3 updates Actemra (-42%) . COVID-19 demand completely washed out in Q3 • Submitted to EMA for approval in SSC-ILD • Shift from IV to SC ongoing Xolair (+8%) • Market leader in asthma biologics and strong • growth in CSU Autoinjector submitted to FDA for approval Esbriet (-48%) • US: Generic competition CER=Constant Exchange Rates; RA=rheumatoid arthritis; IV-intravenous; SC=subcutaneous; CSU-chronic spontaneous urticaria; SSC-ILD=systemic sclerosis-interstitial lung disease Roche 24

View entire presentation